Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein

Vaccine

Volumn 30, Issue 17, 2012, Pages 2749-2759

  Dey, Antu K ^a   Burke, Brian ^a   Sun, Yide ^a   Hartog, Karin ^a   Heeney, Jonathan L ^b   Montefiori, David ^c   Srivastava, Indresh K ^a   Barnett, Susan W ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Carbopol; Gp140; HIV; MF59; SF162

Indexed keywords

CARBOMER; CARBOPOL 971P; ENVELOPE PROTEIN; MIFAMURTIDE; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 140; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL;

ACRYLATES; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; HYDROGEN-ION CONCENTRATION; POLYSORBATES; PROTEIN BINDING; PROTEIN STABILITY; RABBITS; SQUALENE;

EID: 84862777670     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.027     Document Type: Article

References (96)

1. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22(3):339-348.
2. Burke B., Gomez-Roman V.R., Lian Y., Sun Y., Kan E., Ulmer J., et al. Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits. Virology 2009, 387(1):147-156.
3. Spearman P., Lally M.A., Elizaga M., Montefiori D., Tomaras G.D., McElrath M.J., et al. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 2011, 203(8):1165-1173.
4. Gilbert P., Wang M., Wrin T., Petropoulos C., Gurwith M., Sinangil F., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202(4):595-605.
5. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194(12):1661-1671.
6. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4(9):e6999.
7. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
8. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191(5):654-665.
9. Dey A.K., Srivastava IK Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines 2011, 10(2):227-251.
10. Seubert A., Monaci E., Pizza M., O'Hagan D.T., Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008, 180(8):5402-5412.
11. Calabro S., Tortoli M., Baudner B.C., Pacitto A., Cortese M., O'Hagan D.T., et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 2011, 29(9):1812-1823.
12. Seubert A., Calabro S., Santini L., Galli B., Genovese A., Valentini S., et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A 2011, 108(27):11169-11174.
13. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27(25-26):3331-3334.
14. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(7198):1122-1126.
15. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22(3):411-416.
16. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6(5):699-710.
17. O'Hagan D.T., Rappuoli R., De Gregorio E., Tsai T., Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 2011, 10(4):447-462.
18. Ott G. The adjuvant MF59: a ten year perspective 2000, Humana Press, New York, NY, USA.
19. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 1995, 6:277-296.
20. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59 adjuvant. Vaccine 2008, 26(26):3209-3222.
21. Podda A., Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003, 2(2):197-203.
22. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27(45):6291-6295.
23. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(7):563-571.
24. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197(5):667-675.
25. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009, 106(10):3877-3882.
26. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009, 4(2):e4384.
27. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
28. Fragapane E., Gasparini R., Schioppa F., Laghi-Pasini F., Montomoli E., Banzhoff A. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 2010, 17(11):1817-1819.
29. Khurana S., Verma N., Yewdell J.W., Hilbert A.K., Castellino F., Lattanzi M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3(85):85ra48.
30. Keefer M.C., Graham B.S., McElrath M.J., Matthews T.J., Stablein D.M., Corey L., et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1996, 12(8):683-693.
31. Frey S.E., Houghton M., Coates S., Abrignani S., Chien D., Rosa D., et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010, 28(38):6367-6373.
32. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377(9773):1256-1263.
33. Singla A.K., Chawla M., Singh A. Potential applications of carbomer in oral mucoadhesive controlled drug delivery system: a review. Drug Dev Ind Pharm 2000, 26(9):913-924.
34. Rabiskova M., Sedlakova M., Vitkova M., Kuna M. Carbomers and their use in pharmaceutical technology. Ceska Slov Farm 2004, 53(6):300-303.
35. Mumford J.A., Wilson H., Hannant D., Jessett D.M. Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant. Epidemiol Infect 1994, 112(2):421-437.
36. Gualandi G.L., Losio N.M., Muratori G., Foni E. The ability by different preparations of porcine parvovirus to enhance humoral immunity in swine and guinea pigs. Microbiologica 1988, 11(4):363-369.
37. Tollersrud T., Norstebo P.E., Engvik J.P., Andersen S.R., Reitan L.J., Lund A. Antibody responses in sheep vaccinated against Staphylococcus aureus mastitis: a comparison of two experimental vaccines containing different adjuvants. Vet Res Commun 2002, 26(8):587-600.
38. Krashias G., Simon A.K., Wegmann F., Kok W.L., Ho L.P., Stevens D., et al. Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer. Vaccine 2010, 28(13):2482-2489.
39. Cranage M.P., Fraser C.A., Cope A., McKay P.F., Seaman M.S., Cole T., et al. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 2011, 29(7):1421-1430.
40. Srivastava I.K., Stamatatos L., Kan E., Vajdy M., Lian Y., Hilt S., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003, 77(20):11244-11259.
41. Srivastava I.K., Stamatatos L., Legg H., Kan E., Fong A., Coates S.R., et al. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol 2002, 76(6):2835-2847.
42. Dey A.K., David K.B., Klasse P.J., Moore J.P. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 2007, 360(1):199-208.
43. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(5187):1024-1027.
44. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70(2):1100-1108.
45. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75(22):10892-10905.
46. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schulke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001, 75(22):10906-10911.
47. Allaway G.P., Davis-Bruno K.L., Beaudry G.A., Garcia E.B., Wong E.L., Ryder A.M., et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995, 11(5):533-539.
48. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67(7):3978-3988.
49. Cavacini L., Duval M., Song L., Sangster R., Xiang S.H., Sodroski J., et al. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS 2003, 17(5):685-689.
50. Dey A.K., Khati M., Tang M., Wyatt R., Lea S.M., James W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 2005, 79(21):13806-13810.
51. Moore J.P., Jarrett R.F. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res Hum Retroviruses 1988, 4(5):369-379.
52. Moore J.P., Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996, 70(3):1863-1872.
53. Moore J.P., Wallace L.A., Follett E.A., McKeating J.A. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 1989, 3(3):155-163.
54. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79(16):10108-10125.
55. Montefiori DC Measuring HIV neutralization in a luciferase reporter gene assay 2009, Humana Press.
56. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22(19):2489-2493.
57. Otten G.R., Schaefer M., Doe B., Liu H., Srivastava I., Megede J., et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005, 79(13):8189-8200.
58. Gomez-Roman V.R., Florese R.H., Peng B., Montefiori D.C., Kalyanaraman V.S., Venzon D., et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 2006, 43(3):270-277.
59. Xu R., Srivastava I.K., Greer C.E., Zarkikh I., Kraft Z., Kuller L., et al. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses 2006, 22(10):1022-1030.
60. Shu Y., Winfrey S., Yang Z.Y., Xu L., Rao S.S., Srivastava I., et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 2007, 25(8):1398-1408.
61. Barnett S.W., Srivastava I.K., Ulmer J.B., Donnelly J.J., Rappuoli R. Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 2005, 7(14):1386-1391.
62. Lian Y., Srivastava I., Gomez-Roman V.R., Zur Megede J., Sun Y., Kan E., et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005, 79(21):13338-13349.
63. Barnett S.W., Lu S., Srivastava I., Cherpelis S., Gettie A., Blanchard J., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75(12):5526-5540.
64. Nandi A, Sun Y, Hartog K, Zambonelli C, Dubey A, Matsuoka K, et al. Selection and evaluation of HIV-1 Subtype C Early Transmitted Virus gp140 immunogens. manuscript in preparation.
65. Donnelly L., Curran R.M., Tregoning J.S., McKay P.F., Cole T., Morrow R.J., et al. Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine 2011, 29(27):4512-4520.
66. Cranage M.P., Fraser C.A., Stevens Z., Huting J., Chang M., Jeffs S.A., et al. Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 2010, 3(1):57-68.
67. El Sahly H. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 2010, 9(10):1135-1141.
68. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360(12):1191-1199.
69. Nitayaphan S., Khamboonruang C., Sirisophana N., Morgan P., Chiu J., Duliege A.M., et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. Vaccine 2000, 18(15):1448-1455.
70. Grundner C., Pancera M., Kang J.M., Koch M., Sodroski J., Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 2004, 330(1):233-248.
71. Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320(5877):760-764.
72. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
73. McKeage K., Romanowski B. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix(R)): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 2011, 71(4):465-488.
74. De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17(23-24):3094-3101.
75. Minutello M., Senatore F., Cecchinelli G., Bianchi M., Andreani T., Podda A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17(2):99-104.
76. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19(17-19):2673-2680.
77. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8(2):235-247.
78. Harper D.M. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009, 8(12):1663-1679.
79. Jones T. GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection. Curr Opin Mol Ther 2009, 11(3):337-345.
80. Carter N.J., Plosker G.L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 2008, 22(5):279-292.
81. Kuroda E., Ishii K.J., Uematsu S., Ohata K., Coban C., Akira S., et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011, 34(4):514-526.
82. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17(4):479-487.
83. Dupuis M., Murphy T.J., Higgins D., Ugozzoli M., van Nest G., Ott G., et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998, 186(1):18-27.
84. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105(30):10501-10506.
85. Braun W., Nakano M. Antibody formation: stimulation by polyadenylic and polycytidylic acids. Science 1967, 157(3790):819-821.
86. Winchurch R., Braun W. Antibody formation: premature initiation by endotoxin or synthetic polynucleotides in newborn mice. Nature 1969, 223(5208):843-844.
87. Turner W., Chan S.P., Chirigos M.A. Stimulation of humoral and cellular antibody formation in mice by poly Ir:Cr. Proc Soc Exp Biol Med 1970, 133(1):334-338.
88. Diamantstein T., Wagner B., Beyse I., Odenwald M.V., Schulz G. Stimulation of humoral antibody formation by polyanions. II. The influence of sulfate esters of polymers on the immune response in mice. Eur J Immunol 1971, 1(5):340-343.
89. Diamantstein T., Wagner B., L'Age-Stehr J., Beyse I., Odenwald M.V., Schultz G. Stimulation of humoral antibody formation by polyanions. 3. Restoration of the immune response to sheep red blood cells by polyanions in thymectomized and lethally irradiated mice protected with bone marrow cells. Eur J Immunol 1971, 1(4):302-304.
90. Diamantstein T., Ruhl H., Vogt W., Bochert G. Stimulation of B-cells by dextran sulphate in vitro. Immunology 1973, 25(4):743-747.
91. Wetzel G.D., Kettman J.R. Activation of murine B cells. II. Dextran sulfate removes the requirement for cellular interaction during lipopolysaccharide-induced mitogenesis. Cell Immunol 1981, 61(1):176-189.
92. Wetzel G.D., Kettman J.R. Activation of murine B lymphocytes. III. Stimulation of B lymphocyte clonal growth with lipopolysaccharide and dextran sulfate. J Immunol 1981, 126(2):723-728.
93. Khurana S., Chearwae W., Castellino F., Manischewitz J., King L.R., Honorkiewicz A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2(15):15ra5.
94. Coucke D., Schotsaert M., Libert C., Pringels E., Vervaet C., Foreman P., et al. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 2009, 27(8):1279-1286.
95. Lee S.H., Lillehoj H.S., Jang S.I., Lee K.W., Yancey R.J., Dominowski P. The effects of a novel adjuvant complex/Eimeria profilin vaccine on the intestinal host immune response against live E. acervulina challenge infection. Vaccine 2010, 28(39):6498-6504.
96. Garg N.K., Mangal S., Khambete H., Sharma P.K., Tyagi R.K. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul 2010, 4(2):114-128.